Precision Risk Evaluation for Chemotherapy-Induced Neutropenia
Research type
Research Study
Full title
PREDICT-ONC: Precision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool
IRAS ID
349904
Contact name
Francis L Martin
Contact email
Sponsor organisation
Blackpool Teaching Hosp
Clinicaltrials.gov Identifier
10086568, Innovate UK Project No.
Duration of Study in the UK
1 years, 0 months, 30 days
Research summary
Patients with advanced cancers are often treated with chemotherapy which can reduce the effectiveness of the body's own immune system and leave patients exposed to infection. The manufacturers of chemotherapy drugs generally suggest using the same amount of drug for everybody; however, we know that because everyone is different, people end up with more or less of the drug circulating in their blood even after they have been given the same dose.
A software program (a "Dosing Tool") being developed by Physiomics (research partner) aims to eventually provide information to doctors on how certain chemotherapies will affect individual patients, allowing doctors to make smarter decisions about exactly how much drug to give to different people and also how and when to use other expensive drugs that counteract the effect of chemotherapy on the immune system.
In order to make the Dosing Tool work, doctors need to collect information through additional blood tests to assess how individuals respond to their chemotherapy. To support the development of this dosing Tool the aim is to run a clinical trial where women with breast cancer under standard of care, will be monitored for the depletion of a type of white blood cells called neutropenia. For this trial run at Blackpool Victoria hospital, a nurse will travel to patient's home where needed to collect small volumes (a few microliters) of blood. As it can be inconvenient or even impossible for some patients to return to their cancer care centre to have these tests, Physiomics is working with another company, Beyond Blood, which is developing a system to enable patients to obtain blood test results from small samples in a community setting. This portable cell counting (IVD) device is also in development.
We believe a combination of the Dosing Tool and Beyond Blood at-home test may eventually be approved for use to help ensure patients get the best outcomes when they are being treated for breast cancer.
REC name
Wales REC 5
REC reference
24/WA/0347
Date of REC Opinion
6 Jan 2025
REC opinion
Further Information Favourable Opinion